OmniAb, Inc. Common Stock OABI
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $11.00 (+154.0% upside)
Key Stats
- Today's Range
- $4.14 – $4.54
- 50-Day Range
- $1.90 – $4.59
- 52-Week Range
- $1.30 – $4.59
- Volume
- 1.85 million shs
- Average Volume
- 1.46 million shs
- Market Cap
- $625.18 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 2.40
- Price / Sales
- 16.26
Short Interest
- Short Interest
- 1.67%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- $38.46 million
- Net Income
- $-44,270,000
- Net Margin
- -115.12%
- Return on Equity
- -17.01%
- Debt-to-Equity
- —
About OmniAb, Inc. Common Stock
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
Related Stocks
Compare head-to-head: OABI vs MEDP·OABI vs ABSI·OABI vs NRC
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.